With key trials successfully initiated and the balance sheet strengthened in 2025, Curasight is set up for a big 2026. Glioblastoma ph1/2 preliminary efficacy data are due in Q2/26, and uTRACE preliminary data are also due during H1/26. We expect both to be positive overall. We estimate Curasight's DKK 36m cash position at YE-25 to be sufficient to fund operations through the preliminary data readouts for both uTREAT and uTRACE. We reiterate our DKK 14-36 per share valuation range.

Link to the analysis